- Home
- ESPR vs CCIX Comparison
ESPR vs CCIX Comparison
Compare ESPR & CCIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CCIX
- Stock Information
- Founded
- ESPR 2008
- CCIX 2023
- Country
- ESPR United States
- CCIX United States
- Employees
- ESPR N/A
- CCIX N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CCIX
- Sector
- ESPR Health Care
- CCIX
- Exchange
- ESPR Nasdaq
- CCIX Nasdaq
- Market Cap
- ESPR 399.0M
- CCIX 367.7M
- IPO Year
- ESPR 2013
- CCIX 2024
- Fundamental
- Price
- ESPR $2.30
- CCIX $10.26
- Analyst Decision
- ESPR Buy
- CCIX
- Analyst Count
- ESPR 5
- CCIX 0
- Target Price
- ESPR $7.30
- CCIX N/A
- AVG Volume (30 Days)
- ESPR 8.8M
- CCIX 49.6K
- Earning Date
- ESPR 11-07-2024
- CCIX 01-01-0001
- Dividend Yield
- ESPR N/A
- CCIX N/A
- EPS Growth
- ESPR N/A
- CCIX N/A
- EPS
- ESPR N/A
- CCIX N/A
- Revenue
- ESPR $295,451,000.00
- CCIX N/A
- Revenue This Year
- ESPR $186.90
- CCIX N/A
- Revenue Next Year
- ESPR $31.10
- CCIX N/A
- P/E Ratio
- ESPR N/A
- CCIX N/A
- Revenue Growth
- ESPR 187.12
- CCIX N/A
- 52 Week Low
- ESPR $1.58
- CCIX $10.00
- 52 Week High
- ESPR $3.94
- CCIX $11.17
- Technical
- Relative Strength Index (RSI)
- ESPR 44.79
- CCIX N/A
- Support Level
- ESPR $2.12
- CCIX N/A
- Resistance Level
- ESPR $2.54
- CCIX N/A
- Average True Range (ATR)
- ESPR 0.35
- CCIX 0.00
- MACD
- ESPR -0.10
- CCIX 0.00
- Stochastic Oscillator
- ESPR 21.90
- CCIX 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.